NEW YORK (GenomeWeb News) – Eurofins Mediogenomix has licensed co-exclusive rights to Orion Diagnostica's strand invasion-based amplification (SIBA) technology, the firms announced today.
Espoo, Finland-based Orion Diagnostica owns the global rights for the SIBA isothermal nucleic acid detection technology in all fields, the partners noted. Financial and other terms of the agreement were not disclosed.
"The SIBA technology and the associated expertise of Orion Diagnostica are an excellent fit for Eurofins," Peter Persigehl, managing director of Eurofins Medigenomix, which is part of the Eurofins Scientific group. "The cooperation will allow us to broaden Eurofins' portfolio with innovative analytical solutions particularly in the area of DNA-based authenticity testing for food and related products."
The SIBA technology relies on the recombinase-dependent invasion of an oligonucleotide into the target nucleic acid, leading to dissociation of the double-stranded nucleic acid. This enables specific primers to amplify the target exponentially by the action of the polymerase, according to Orion.